Patents by Inventor Arusha OLOUMI

Arusha OLOUMI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarkers of cancer metastasis
    Patent number: 8735061
    Abstract: There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-?3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1?), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-?3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1?, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 27, 2014
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Yuanmei Lou, Paul Christopher McDonald, Arusha Oloumi, Shoukat Dedhar
  • BIOMARKERS OF CANCER METASTASIS
    Publication number: 20120301891
    Abstract: There is provided a method for determining tumour metastatic potential using biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-?3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1?), and tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-?3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1?, or TNC may be indicators of high metastatic potential. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.
    Type: Application
    Filed: August 10, 2012
    Publication date: November 29, 2012
    Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Yuanmei LOU, Paul Christopher MCDONALD, Arusha OLOUMI, Shoukat DEDHAR
  • BIOMARKERS OF CANCER METASTASIS
    Publication number: 20100317533
    Abstract: There is provided a panel of biomarkers of tumour metastasis comprising any two of carbonic anhydrase-9 (CAIX), vascular endothelial growth factor C (VEGF-C), ephrin A5 (EFNA5), eph receptor B2 (EPHB2), transforming growth factor beta 3 (TGF-?3), pyruvate dehydrogenase kinase isoenzyme-3 (PDK3), carbonic anhydrase-12 (CAXII), keratin 14 (KRT14), hypoxia inducible factor 1 alpha subunit (HIF-1?), or tenascin C (TNC). CAIX, VEGF-C, EFNA5, EPHB2, TGF-?3 or PDK3 may be indicators of moderate metastatic potential, while CAXII, KRT14, HIF-1?, or TNC may be indicators of high metastatic potential. There is also provided a method of determining risk of tumour metastasis using the aforementioned biomarkers is also provided. The biomarkers may be used in diagnosis, prognosis, treatment selection, or to test putative therapeutics. The biomarkers may be used to assess malignancies or cancers having hypoxic regions, such as breast cancer.
    Type: Application
    Filed: June 7, 2010
    Publication date: December 16, 2010
    Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Yuanmei LOU, Paul Christopher MCDONALD, Arusha OLOUMI, Shoukat DEDHAR